IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.